“The future belongs to those who are willing to explore new possibilities with both courage and responsibility.”
Every generation faces defining moments—moments when scientific discovery, public policy, and human need align to create the possibility for transformational change. We believe we are living through one of those moments today. Across the United States and around the world, societies are confronting an unprecedented mental health crisis. Veterans continue to struggle with post-traumatic stress disorder at alarming rates. Families are losing loved ones to opioid addiction and overdose. Millions of people are also living with neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, ALS, and multiple sclerosis, often with limited therapeutic options capable of changing the course of their illness.
For decades, medicine has made important progress in helping patients manage symptoms. Yet many of these conditions continue to impose an enormous human and economic burden. Today, a growing body of scientific research is encouraging us to ask a different question:
What if we could help the brain heal itself?
One of the most promising compounds being investigated to answer that question is ibogaine.
A Remarkable Molecule Deserving Serious Science
Ibogaine is a naturally occurring alkaloid derived from the root bark of Tabernanthe iboga, a shrub native to Central West Africa, where it has been used for generations in traditional ceremonial practices. Unlike conventional psychiatric medications that often require continuous daily treatment, ibogaine appears to interact with multiple neurological systems simultaneously. Researchers are actively studying its potential effects on neuroplasticity, addiction pathways, trauma processing, inflammation, and neural repair. Around the world, scientists are investigating its potential applications in:
- Opioid use disorder
- Alcohol and other substance use disorders
- Post-traumatic stress disorder
- Depression
- Traumatic brain injury
- Neurodegenerative diseases, including Parkinson’s disease
Much remains to be learned. Ibogaine is not currently approved by the U.S. Food and Drug Administration, and rigorous clinical research remains essential to determine its safety, effectiveness, and appropriate medical applications. But the scientific momentum surrounding ibogaine is undeniable. Leading universities, biotechnology companies, clinicians, and governments are investing unprecedented resources to better understand this extraordinary compound. That is precisely how medical innovation should evolve—not through ideology or hype, but through evidence.
Why This Mission Is Personal
For me, this conversation is about far more than science or public policy. It is personal. Several years ago, I was diagnosed with Parkinson’s disease. Like countless others facing a progressive neurological condition, I found myself asking difficult questions: Would my symptoms continue to worsen? Would I lose my independence? Would I still be able to build companies, lead organizations, and enjoy time with my family? Those questions changed my life. They also changed my perspective. I became determined to understand every promising avenue of research—not miracle cures or unsupported claims, but therapies worthy of serious scientific investigation. That journey eventually led me to ibogaine.
Under careful medical supervision, I underwent treatment and later continued with a medically supervised microdosing protocol. While my Parkinson’s has certainly not been cured, the improvements I experienced were significant. My tremor diminished considerably. My energy improved. My mental clarity returned. I regained confidence. Most importantly, I recovered something that every patient needs but too often loses after receiving a diagnosis:
Hope.
I share my experience with humility because I understand its limitations. One person’s experience is not scientific proof. It should never replace well-designed clinical trials or evidence-based medicine. But personal experiences often inspire important scientific questions. Why are patients reporting these changes? What biological mechanisms could explain them? Could ibogaine open entirely new pathways for treating neurodegenerative diseases? Those questions deserve rigorous investigation. Patients deserve answers grounded in science. That conviction ultimately became one of the driving forces behind the work of the Pravan Foundation.
A New Era of Innovation
Earlier this year, the United States entered a new chapter in the development of psychedelic medicine. President Donald Trump’s Executive Order on advancing innovative therapies directed federal agencies to accelerate research into promising treatments for serious mental illnesses, reduce unnecessary barriers to clinical investigation, and encourage collaboration among government, academia, and the private sector. The initiative specifically recognizes emerging psychedelic therapies—including ibogaine—as areas worthy of accelerated scientific exploration. This represents an important shift. For the first time, innovation in psychedelic medicine is no longer occurring solely at the margins of scientific research. It is becoming part of the national conversation about the future of healthcare.
Why Puerto Rico Can Lead
Puerto Rico possesses a combination of strengths found in very few places in the world. Our Island has:
- One of the world’s most important pharmaceutical manufacturing ecosystems
- Outstanding physicians and healthcare professionals
- Highly respected universities and researchers
- A growing biotechnology community
- Strong connections to both the United States and Latin America
- A long history of medical innovation
These advantages create an extraordinary opportunity. Puerto Rico can become far more than a place where innovative therapies are administered. It can become a global center for research, education, physician training, pharmaceutical development, clinical innovation, and responsible regulation. The opportunity extends far beyond healthcare. It represents economic development, scientific leadership, workforce development, international collaboration, and hope for patients around the world.
Building an Ecosystem, Not Just a Treatment
At the Pravan Foundation, we have never believed that meaningful change comes from a single molecule. Real transformation happens when an entire ecosystem comes together:
- Researchers
- Physicians
- Universities
- Government
- Hospitals
- Biotechnology companies
- Patients
- Philanthropists
- Community organizations
When these groups collaborate around a common mission, innovation accelerates. That is the future we envision.
Responsibility Must Guide Innovation
As enthusiasm around psychedelic medicine continues to grow, we must remain grounded. Scientific integrity must always come before excitement. Patient safety must always come before commercial opportunity. Every therapy should be evaluated through rigorous research, ethical oversight, transparent reporting, and careful clinical implementation. Innovation without responsibility can be dangerous. But responsibility without innovation leaves millions of patients waiting for answers they desperately need. The future requires both.
A Future Worth Building
Every morning, millions of people wake up carrying burdens that few others can fully understand. The veteran reliving trauma. The parent struggling with addiction. The family watching a loved one slowly disappear into Alzheimer’s disease. The person living with Parkinson’s, wondering whether tomorrow’s symptoms will be worse than today’s. I know that feeling. I am one of those patients. That is why this mission means so much to me. I believe Puerto Rico has an opportunity unlike any in its history—to become a place where science and compassion work hand in hand. A place where groundbreaking research is conducted responsibly. Where physicians receive world-class training. Where patients gain access to innovative therapies through ethical, evidence-based programs.
Where discoveries made on our Island contribute to healing people across the world. This is not simply about ibogaine. It is about choosing innovation over complacency. Hope over resignation. Science over stigma. The future of medicine has always belonged to those willing to ask difficult questions and pursue better answers. My hope is that Puerto Rico chooses to lead that future. At the Pravan Foundation, we are committed to doing everything we can to help make that vision a reality.
